POPULATION SCREENING FOR CHRONIC DISEASE MAXIMISING BENEFITS, MINIMISING HARMS Public Health Association of Australia (PHAA) hold conference on current and future advances in population screening
With
Adjunct Professor Terry Slevin, Chief Executive Officer
Public Health Association of Australia
Australian Health Journal Segment
Filmed in Sydney | March 2025
Population screening is an important contributor to advancing health outcomes through the early detection of and successful intervention for chronic disease. The evolution of science, technology and evidence relating to diseases which are or may be amenable to a population screening approach deserve broad discussion and the sharing of expertise and evidence. They also warrant close scrutiny in context of health policy and health resource allocation considerations.
There are established (and proposed) screening programs relevant to a range of diseases, notably breast, cervix, bowel cancer, and more recently for skin and lung cancer screening. There are a number of other chronic diseases where as new technologies are emerging and evidence is being gathered to support organised screening, (including but not limited to diabetes, CKD, MAFLD as well as cardiovascular and other risk assessment for primary prevention in general practice.
Population-based criteria for screening, based on WHO criteria and the Australian Population Based Screening Framework, aim to ensure that the benefits of screening outweigh and minimise any potential harms. These criteria are well understood by those involved in established screening programs and advocates for emerging screening programs are keen to learn from past experience how to compile evidence, design, implement and monitor programs, as well as ensure equitable participation. Similarly, there is much to learn from emerging programs and new technologies for those involved in established programs where adopting advances in evidence and technology can be challenging and perceived as slower.
In March, Public Health Association of Australia (PHAA) convened Screening Conference Conference 2025 with the theme of ‘Population Screening for Chronic Disease – Maximising Benefits, Minimising Harms’.
The conference provided opportunities for attendees to exchange information on population screening and learn from each other’s experience, across a range of disciplines. Those in attendance and presenting came from research, society, Government, program delivery, policy, consumers and clinicians.
Source: Adapted from Screening 2025 Conference website (PHAA operated)
-
New clinical research entity first to operate across both Australia and New Zealand
Over the past 30 years, 18,000 clinical trials that have been registered in Australia, with the sector contributing $1.4 billion to Australia’s economy annually. Trials are a critical aspect of evidence-based medicine, and are essential for testing how new treatments, tests and vaccines will work. In New Zealand they contribute $146 million to the New Zealand economy.
To capitalise on this unique position and growth, a coordinated multi-site clinical research operation was missing, until now.
-
Still seeking outcomes after 6th Stoma Appliance Scheme Schedule Review
50,000 Australians have undergone the trauma and challenge of having a stoma inserted. Whilst the Australian Government invests in the appliances and products they need through the Stoma Appliance Scheme (SAS), this list is dated and doesn’t include as many of the products available in other countries. A new report commissioned by the Stoma Industry Association (SIA) shows Australia lagging countries such as the United Kingdom, Canada and Spain in supporting ostomates (people with a stoma).
-
Sovereign capability uplifted
Skilled labour, in particular skilled in the manufacture of MTP products, namely competency in Good Manufacturing Practice (GMP), was identified as one of the key priorities, according to Jarrod Belcher, Director of the REDI Program at MTPConnect. Through a competitive process, MTPConnect selected additional industry training providers to deliver new programs addressing key skills gaps in the sector workforce.
Launched in September 2022, one of these programs is GMP Uplift developed by the Centre for Biopharmaceutical Excellence (CBE). CBE bring experience across large and small Biologics, Pharmaceuticals and Regenerative Medicine companies, both in consulting and GMP related enterprise training. CBE staff also have extensive experience in GMP operations, compliance, auditing and QMS design, a wide industry network for guest lecturers and readily available case studies.
